Key Points GAAP revenue surged to $4.0 million in Q2 2025, beating analyst expectations by 381.9%. GAAP net loss per share improved to $(0.50) in Q2 2025, slightly better than the estimated $(0.52).

LMO2 is an intrinsically disordered transcription factor activated in T cell leukaemia that is difficult to target. It forms part of a multiprotein complex that has bipartite DNA binding through ...

The Fund returned approximately +14% during the second quarter, bringing our YTD returns to under +1%. Read more here.

Trailhead Biosystems expands iPSC-derived portfolio with TrailBio Hematopoietic Progenitor Cells: Beachwood, Ohio Wednesday, August 6, 2025, 16:00 Hrs [IST] Trailhead Biosystems, ...

It is already well-known that when a mother experiences inflammation during pregnancy, her child is more likely to develop ...